LINC01869

Across TCGA pan-cancer cohorts, LINC01869 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated LINC01869 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher LINC01869 RNA is associated with better overall survival. In most high-consensus cancer types, elevated LINC01869 expression acts as an unfavorable survival marker, although some lineages such as PAAD and ESCA show a favorable association.

PAAD, ESCA, and KIRP are the cancer types where LINC01869 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.531	0.267	.001	64	view →
ESCA	DFS	Tertile	All	1.000	0.460	.004	50	view →
KIRP	DFS	Median	II,III,IV	0.534	0.803	.004	45	view →
LUAD	OS	Median	II,III,IV	0.661	0.383	<.001	34	view →
UCS	OS	Median	IV	0.404	0.752	.013	30	view →
HNSC	OS	Tertile	All	0.621	0.845	.007	19	view →
KIRC	OS	Tertile	All	0.592	0.732	.015	18	view →
PRAD	DFS	Quartile	All	0.684	0.897	<.001	18	view →
MESO	OS	Quartile	III,IV	0.256	0.543	.003	13	view →
LGG	OS	Median	All	0.853	0.917	.010	10	view →
SKCM	DFS	Median	IV	0.773	0.147	.016	10	view →
THCA	DFS	Tertile	II,III,IV	0.781	0.934	.016	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

LINC01869–PAAD (OS)

Open the PAAD breakdown →